Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Melissa Accordino, MD
Columbia University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham (uab)
Birmingham, Alabama, United States
- Northside Hospital, Inc.
Atlanta, Georgia, United States
- Northwestern Medical Hospital
Chicago, Illinois, United States
- the University of Kansas Cancer Center
Westwood, Kansas, United States
- Northwell Health/monter Cancer Center
Lake Success, New York, United States
- Columbia University Medical Center
New York, New York, United States
- Mount Sinai Medical Center
New York, New York, United States
- Nyu Langone Medical Center
New York, New York, United States
- Weill Cornell Medical Center
New York, New York, United States
- Stony Brook Cancer Center
Stony Brook, New York, United States
- Albert Einstein University / Montefiore Medical Center
The Bronx, New York, United States
- Vanderbilt-Ingham Cancer Center
Nashville, Tennessee, United States
- University of Wisconsin School of Medicine
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2016
- Primary completion
- 4 Jan 2022
- Completion
- 4 Jan 2022
- Last update posted
- 6 Dec 2024
- Registered enrollment
- 169
- Registry id
- NCT02632045
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.